KRAS and plasma cell myeloma: Previous studies have elucidated that increased lactate metabolism was enriched in TP53-mutated patients with multiple myeloma (Shah et al. 2018) and KRAS-mutated patients with lung adenocarcinoma (McCleland et al. 2013), implicating the potential association of TP53 and KRAS mutations with lactate metabolism in iCCA.